Drug Trial Radar · NCT00185419
A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception
Last checked: Nov 20, 2026Latest source record: Jan 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
842
Actual
Start
Nov 2003
Primary completion
Mar 2006
Study completion Mar 2006
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Sep 16, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 20 years, up to 35 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women
Conditions
- Contraception
Interventions
YasminDrug
30 µg ethinylestradiol, 3mg drospirenone
MarvelonDrug
30 µg ethinylestradiol, 150 µg desogestrel
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary efficacy variable is the comparison of cycle control from randomisation to cycle 13. This will be based on the number of subjects reporting at least 1 unexpected intracyclic bleeding episode between cycles 2 to 13.Time frame: 13 treatment cycles (1 cycle= 28 days)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Ask Contact, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.